| 1 | 9021668 | [Mutagenicity study of a new antineoplastic agent S-1, and its components, CDHP, and Oxo]. | J Toxicol Sci | 1996 Nov |
2 |
| 2 | 9140762 | Determination of S-1 (combined drug of tegafur, 5-chloro-2,4-dihydroxypyridine and potassium oxonate) and 5-fluorouracil in human plasma and urine using high-performance liquid chromatography and gas chromatography-negative ion chemical ionization mass spectrometry. | J Chromatogr B Biomed Sci Appl | 1997 Mar 28 |
2 |
| 3 | 10363584 | Therapeutic effect of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) on liver metastasis of xenotransplanted human colon carcinoma. | Jpn J Cancer Res | 1999 Apr |
3 |
| 4 | 10473078 | Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug. | Clin Cancer Res | 1999 Aug |
2 |
| 5 | 10545788 | An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. The S-1 Gastrointestinal Cancer Study Group. | Oncology | 1999 Oct |
1 |
| 6 | 10901361 | Phase II study of S-1, a novel oral fluorophyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group. | Br J Cancer | 2000 Jul |
1 |
| 7 | 11290431 | The significance of dihydropyrimidine dehydrogenase (DPD) activity in bladder cancer. | Eur J Cancer | 2001 Mar |
2 |
| 8 | 11497250 | Possible regulation of 5-fluorouracil-induced neuro- and oral toxicities by two biochemical modulators consisting of S-1, a new oral formulation of 5-fluorouracil. | Anticancer Res | 2001 May-Jun |
2 |
| 9 | 12044515 | Enhancement of the antitumour activity of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase activity (DPD) using 5-chloro-2,4-dihydroxypyridine (CDHP) in human tumour cells. | Eur J Cancer | 2002 Jun |
11 |
| 10 | 12111108 | Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor agent in animal model and in patients with impaired renal function. | Cancer Chemother Pharmacol | 2002 Jul |
4 |
| 11 | 12538461 | Phase I study with pharmacokinetics of S-1 on an oral daily schedule for 28 days in patients with solid tumors. | Clin Cancer Res | 2003 Jan |
1 |
| 12 | 12739060 | Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors. | Cancer Chemother Pharmacol | 2003 Jul |
4 |
| 13 | 12751387 | Significance of dihydropyrimidine dehydrogenase activity in renal cell carcinoma. | Eur J Cancer | 2003 Mar |
2 |
| 14 | 12763215 | Phase II trial with S-1 in chemotherapy-naïve patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG). | Eur J Cancer | 2003 Jun |
2 |
| 15 | 12775012 | S-1 in gastric cancer: a comprehensive review. | Gastric Cancer | 2003 |
6 |
| 16 | 12853891 | Effect of combination of TS-1 and low-dose cisplatin on sarcoma-180 mouse sarcoma. | Anticancer Drugs | 2003 Jul |
1 |
| 17 | 14551502 | Dihydropyrimidine dehydrogenase inhibition as a strategy for the oral administration of 5-fluorouracil: utility in the treatment of advanced colorectal cancer. | Anticancer Drugs | 2003 Oct |
1 |
| 18 | 14650374 | Comparison of the pharmacokinetics of S-1, an oral anticancer agent, in Western and Japanese patients. | J Pharmacokinet Pharmacodyn | 2003 Aug |
1 |
| 19 | 15075664 | The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors. | Anticancer Drugs | 2004 Feb |
3 |
| 20 | 15160338 | Phase II study of oral S-1 for treatment of metastatic colorectal carcinoma. | Cancer | 2004 Jun 1 |
1 |
| 21 | 15331922 | Safety and efficacy of S-1, a novel oral fluorouracil antitumor drug, for a chronic renal failure patient maintained on hemodialysis. | Oncology | 2004 |
2 |
| 22 | 15550867 | A phase II study of S-1 in patients with metastatic breast cancer--a Japanese trial by the S-1 Cooperative Study Group, Breast Cancer Working Group. | Breast Cancer | 2004 |
1 |
| 23 | 15949589 | Role of dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine against non-small cell lung cancer--in correlation with the tumoral expression of thymidylate synthase and dihydropyrimidine dehydrogenase. | Lung Cancer | 2005 Jul |
3 |
| 24 | 15993511 | The role of thymidylate synthase and dihydropyrimidine dehydrogenase in resistance to 5-fluorouracil in human lung cancer cells. | Lung Cancer | 2005 Sep |
3 |
| 25 | 16315929 | [A trial of TS-1 administration on the basis of the pharmacokinetic study for an advanced gastric cancer patient with impaired renal function]. | Gan To Kagaku Ryoho | 2005 Oct |
4 |
| 26 | 16317557 | Potassium oxonate, an enzyme inhibitor compounded in S-1, reduces the suppression of antitumor immunity induced by 5-fluorouracil. | Cancer Chemother Pharmacol | 2006 Aug |
1 |
| 27 | 16549996 | Effect of gastrectomy on the pharmacokinetics of 5-fluorouracil and gimeracil after oral administration of S-1. | Anticancer Drugs | 2006 Apr |
1 |
| 28 | 16897967 | [Timeline from discovery of 5-FU to development of an oral anticancer agent S-1 and its drug concept]. | Gan To Kagaku Ryoho | 2006 Jun |
1 |
| 29 | 16897969 | [Pharmacokinetics of S-1]. | Gan To Kagaku Ryoho | 2006 Jun |
2 |
| 30 | 16897986 | [S-1 as a single agent for colorectal cancer]. | Gan To Kagaku Ryoho | 2006 Jun |
1 |
| 31 | 16898001 | [Combination chemotherapy with S-1 and cisplatin for non-small cell lung cancer]. | Gan To Kagaku Ryoho | 2006 Jun |
1 |
| 32 | 17092280 | The significance of the expression of dihydropyrimidine dehydrogenase in prostate cancer. | BJU Int | 2007 Mar |
2 |
| 33 | 17603216 | Development of a pharmacokinetic model to optimize the dosage regimen of TS-1, a combination preparation of tegafur, gimeracil and oteracil potassium. | Drug Metab Pharmacokinet | 2007 Jun |
3 |
| 34 | 17699726 | Alteration of dihydropyrimidine dehydrogenase expression by IFN-alpha affects the antiproliferative effects of 5-fluorouracil in human hepatocellular carcinoma cells. | Mol Cancer Ther | 2007 Aug |
6 |
| 35 | 17708166 | Consumer-directed health plans: what happened? | Healthc Financ Manage | 2007 Aug |
1 |
| 36 | 17940834 | Synergistic antitumor effect of combined 5-fluorouracil (5-FU) with 5-chloro-2,4-dihydroxypyridine on 5-FU-resistant gastric cancer cells: possible role of a dihydropyrimidine dehydrogenase-independent mechanism. | J Gastroenterol | 2007 Oct |
1 |
| 37 | 17982671 | Epigenetic regulation of chemosensitivity to 5-fluorouracil and cisplatin by zebularine in oral squamous cell carcinoma. | Int J Oncol | 2007 Dec |
2 |
| 38 | 18172246 | Can inhibiting dihydropyrimidine dehydrogenase limit hand-foot syndrome caused by fluoropyrimidines? | Clin Cancer Res | 2008 Jan 1 |
2 |
| 39 | 18309485 | High intratumoral dihydropyrimidine dehydrogenase mRNA levels in pancreatic cancer associated with a high rate of response to S-1. | Cancer Chemother Pharmacol | 2008 Dec |
2 |
| 40 | 18799915 | [Case report of gastric cancer patient who suffered life-threatening adverse events including severe myelosuppression during neoadjuvant chemotherapy with S-1 and CDDP combination]. | Gan To Kagaku Ryoho | 2008 Sep |
3 |
| 41 | 19052037 | Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas. | Jpn J Clin Oncol | 2009 Jan |
1 |
| 42 | 19093184 | Successful treatment of advanced gallbladder cancer with an anticancer drug S-1: assessment based on intratumoral gene. | Int J Clin Oncol | 2008 Dec |
2 |
| 43 | 19243284 | S-1: a promising new oral fluoropyrimidine derivative. | Expert Opin Investig Drugs | 2009 Mar |
1 |
| 44 | 19632949 | S-1: a new oral fluoropyrimidine in the treatment of patients with advanced non-small-cell lung cancer. | Clin Lung Cancer | 2009 Jul |
1 |
| 45 | 19724848 | S-1 mediates the inhibition of lymph node metastasis in oral cancer cells. | Oncol Rep | 2009 Oct |
4 |
| 46 | 19822965 | Simultaneous determination of tegafur and gimeracil in human plasma by liquid chromatography/tandem mass spectrometry. | Anal Sci | 2009 Oct |
1 |
| 47 | 19921195 | Can the 2-(13)C-uracil breath test be used to predict the effect of the antitumor drug S-1? | Cancer Chemother Pharmacol | 2010 Jul |
1 |
| 48 | 20559897 | Phase 1/2 clinical study of irinotecan and oral S-1 (IRIS) in patients with advanced gastric cancer. | Adv Ther | 2010 Jul |
1 |
| 49 | 21378348 | A phase I study evaluating the effect of CDHP as a component of S-1 on the pharmacokinetics of 5-fluorouracil. | Anticancer Res | 2011 Feb |
5 |
| 50 | 21487460 | Transient effectiveness of an oral 5-Fluorouracil derivative, s-1, for epirubicin, cyclophosphamide and Paclitaxel refractory skin metastases from possible occult breast cancer in a male. | Case Rep Dermatol | 2011 Feb 23 |
1 |